MARKET

FGEN

FGEN

FibroGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

37.82
+0.03
+0.08%
Opening 15:16 11/21 EST
OPEN
38.07
PREV CLOSE
37.79
HIGH
38.11
LOW
37.03
VOLUME
190.93K
TURNOVER
--
52 WEEK HIGH
61.23
52 WEEK LOW
32.33
MARKET CAP
3.30B
P/E (TTM)
91.62
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of FGEN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

FGEN News

  • FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm
  • Business Wire.6d ago
  • Edited Transcript of FGEN earnings conference call or presentation 11-Nov-19 10:00pm GMT
  • Thomson Reuters StreetEvents.11/14 18:37
  • HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud
  • GlobeNewswire.11/14 01:03
  • Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors
  • Business Wire.11/14 00:00

More

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
+0.28%

Hot Stocks

Name
Price
%Change

About FGEN

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
More

Webull offers FibroGen Inc (FGEN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.